p.100 抽出テキスト

reverse remodeling. Sci Rep 2018; 8: 1998. PMID: 29386531 234. 森田啓行.心不全の原因としてのタイチン遺伝子変異.循環器内科2019; 86: 114-119. 235. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 366: 619- 628. PMID: 22335739 236. Schafer S, de Marvao A, Adami E, et al. Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet 2017; 49: 46-53. PMID: 27869827 237. Haggerty CM, Damrauer SM, Levin MG, et al. Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation 2019; 140: 42-54. PMID: 31216868 238. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019; 16: e301-e372. PMID: 31078652 239. Krahn AD, Wilde AAM, Calkins H, et al. Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Clin Electrophysiol 2022; 8: 533-553. PMID: 35450611 240. Zorzi A, Cipriani A, Bariani R, et al. Role of Exercise as a Modulating Factor in Arrhythmogenic Cardiomyopathy. Curr Cardiol Rep 2021; 23: 57. PMID: 33961139 241. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121: 1533-1541. PMID: 20172911 242. 日本循環器学会 / 日本不整脈心電学会.2022 年改訂版 不整脈の診断とリスク評価に関するガイドライン.https://www.j-circ.or.jp/ cms/wp-content/uploads/2022/03/JCS2022_Takase.pdf 243. Corrado D, van Tintelen PJ, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020; 41: 1414-1429. PMID: 31637441 244. ClinGen. https://clinicalgenome.org/ 245. James CA, Jongbloed JDH, Hershberger RE, et al. International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circ Genom Precis Med 2021; 14: e003273. PMID: 33831308 246. Nakajima T, Kaneko Y, Irie T, et al. Compound and digenic heterozygosity in desmosome genes as a cause of arrhythmogenic right ventricular cardiomyopathy in Japanese patients. Circ J 2012; 76: 737-743. PMID: 22214898 247. Wada Y, Ohno S, Aiba T, et al. Unique genetic background and outcome of non-Caucasian Japanese probands with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Mol Genet Genomic Med 2017; 5: 639-651. PMID: 29178656 248. Haywood AF, Merner ND, Hodgkinson KA, et al. Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. Eur Heart J 2013; 34: 1002-1011. PMID: 23161701 249. Verstraelen TE, van Lint FHM, Bosman LP, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg 14del mutation carriers-reaching the frontiers of individual risk prediction. Eur Heart J 2021; 42: 2842-2850. PMID: 34113975 250. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace 2022; 24: 1307-1367. PMID: 35373836 251. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79: 372-389. PMID: 35086660 252. Koike H, Katsuno M. Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies. Neurol Ther 2020; 9: 317-333. PMID: 32948978 253. Koike H, Misu K, Ikeda S, et al. Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met 30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002; 59: 1771-1776. PMID: 12433265 254. Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol 2018; 265: 134-140. PMID: 29177547 255. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78: 637-643. PMID: 22345221 256. Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val 30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012; 83: 152-158. PMID: 22228785 257. Yamashita T, Ueda M, Nomura T, et al. Natural history and longterm effects of variant protein reduction in non-V 30M ATTR amyloidosis. Neurology 2019; 93: 714-716. PMID: 31562191 258. Kelly JW. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 1997; 5: 595-600. PMID: 9195890 259. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73-85. PMID: 15820680 260. 日本循環器学会.2020 年版 心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/ 2020/ 02/ JCS2020_Kitaoka.pdf 261. fabry-database.org. Fabry mutants list. http://fabry-database.org/ mutants/ 262. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123: 416-427. PMID: 29530533 263. Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β : data from the Fabry Registry. J Med Genet 2016; 53: 495-502. PMID: 26993266 264. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’ s disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-293. PMID: 7596372 265. Doheny D, Srinivasan R, Pagant S, et al. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet 2018; 55: 261-268. PMID: 29330335 266. Kubo T, Amano M, Takashio S, et al. A retrospective investigation to establish new screening approach for the detection of patients at high risk of Fabry disease in male left ventricular hypertrophy patients. J Cardiol 2022; 80: 325-331. PMID: 35643740 267. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399-2403. PMID: 18154965 268. Hagège AA, Caudron E, Damy T, et al. FOCUS study investigators. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart 2011; 97: 131-136. PMID: 21062768 269. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89: 44-54. PMID: 25974833 270. Schapira AH. Mitochondrial diseases. Lancet 2012; 379: 1825- 1834. PMID: 22482939 271. Ng YS, Turnbull DM. Mitochondrial disease: genetics and management. J Neurol 2016; 263: 179-191. PMID: 26315846 272. Mazzaccara C, Mirra B, Barretta F, et al. Molecular Epidemiology of Mitochondrial Cardiomyopathy: A Search Among Mitochondrial and Nuclear Genes. Int J Mol Sci 2 0 2 1 ; 2 2 : 5 7 4 2 . PMID: 34072184 273. Bates MG, Bourke JP, Giordano C, et al. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J 2012; 33: 3023-3033. PMID: 22936362 274. Rossignol R, Faustin B, Rocher C, et al. Mitochondrial threshold effects. Biochem J 2003; 370: 751-762. PMID: 12467494 275. Takeda A. Mitochondrial Cardiomyopathy. J Pediatr Cardiol Card Surg 2020; 4: 53-62. 276. 難病情報センター.ミトコンドリア病.https://www.nanbyou. or.jp/wp-content/uploads/upload_files/File/ 021- 201704-kijyun. pdf 277. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008; 372: 1342-1353. PMID: 18929906 278. 日本先天代謝異常学会.ポンペ病診療ガイドライン2018.https:// jsimd.net/pdf/pompe2018.pdf 279. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004; 144 Suppl: S35-S43. PMID: 15126982 280. 厚生労働科学研究費補助金 難治性疾患等政策研究事業「希少難治性筋疾患に関する調査研究」班.自己貪食空胞性ミオパチー診療の手引き.https://www.neurology-jp.org/guidelinem/pdf/avm_ tebiki.pdf 281. Rowland TJ, Sweet ME, Mestroni L, et al. Danon disease dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci 2016; 129: 2135-2143. PMID: 27165304 282. D’souza RS, Levandowski C, Slavov D, et al. Danon disease: Clinical features, evaluation, and management. Circ Heart Fail 2014; 7: 843-849. PMID: 25228319 283. Boucek D, Jirikowic J, Taylor M. Natural history of Danon